Arteris

Positives: disciplined emphasis on organic R&D and field application engineering to expand product breadth and ease of deployment, plus a strategically coherent acquisition of Cycuity to add hardware security assurance across the SoC lifecycle.

Negatives: dilution stepped up in 1H 2026 via an at‑the‑market equity program raising about 72.5 million, and non‑GAAP operating losses persist as the company scales. We expect continued selective M&A and reinvestment ahead of sustained profitability. On net, strategy is sound but dilution and the timing to full profitability temper the score.